• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝硬化腹水:发病机制与管理

Cirrhotic ascites: pathogenesis and management.

作者信息

Garcia-Tsao G

机构信息

Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06520, USA.

出版信息

Gastroenterologist. 1995 Mar;3(1):41-54.

PMID:7743121
Abstract

The pathogenesis of ascites can be divided into (1) factors that favor efflux of fluid from the vascular into the peritoneal space (sinusoidal hypertension, hypoalbuminemia), (2) factors that favor accumulation of fluid in the peritoneal cavity (thoracic duct insufficiency), and (3) factors responsible for repletion of the intravascular volume, and thereby continuous formation of ascites (sodium and water retention). Ascites is perhaps the one complication of cirrhosis with the lowest therapeutic priority. Current therapy of ascites is mainly directed at attaining a negative sodium balance (sodium restriction, diuretics) or at removing intraperitoneal fluid and returning it or its components back to the systemic circulation (large volume paracentesis accompanied by plasma volume expanders, peritoneovenous shunt, ascites "recycling" procedures). Future studies of ascites should investigate the usefulness of peripheral vasoconstrictors and nonsurgical side-to-side portosystemic shunting to relieve sinusoidal hypertension (transjugular intrahepatic portosystemic shunt). More than 90% of patients respond to diuretics and salt restriction. Other therapeutic measures should be directed at the 10% of patients with ascites refractory to diuretics. Prognosis in these patients is poor, and liver transplantation should be contemplated.

摘要

腹水的发病机制可分为

(1)促使液体从血管内流入腹腔的因素(肝窦高压、低白蛋白血症);(2)促使液体在腹腔内积聚的因素(胸导管功能不全);(3)负责补充血管内容量并由此持续形成腹水的因素(钠和水潴留)。腹水可能是肝硬化并发症中治疗优先级最低的一种。目前腹水的治疗主要旨在实现负钠平衡(限制钠摄入、使用利尿剂),或去除腹腔内液体并使其或其成分回到体循环(大量腹腔穿刺放液并辅以血浆扩容剂、腹腔静脉分流术、腹水“再循环”程序)。未来对腹水的研究应探讨外周血管收缩剂和非手术性侧侧门体分流术缓解肝窦高压(经颈静脉肝内门体分流术)的有效性。超过90%的患者对利尿剂和限盐治疗有反应。其他治疗措施应针对10%对利尿剂难治的腹水患者。这些患者的预后较差,应考虑肝移植。

相似文献

1
Cirrhotic ascites: pathogenesis and management.肝硬化腹水:发病机制与管理
Gastroenterologist. 1995 Mar;3(1):41-54.
2
Treatment of ascites in cirrhosis. Diuretics, peritoneovenous shunt, and large-volume paracentesis.肝硬化腹水的治疗。利尿剂、腹腔静脉分流术及大量腹腔穿刺放液术。
Gastroenterol Clin North Am. 1992 Mar;21(1):237-56.
3
Ascites: diagnosis and management.腹水:诊断与管理
Med Clin North Am. 2009 Jul;93(4):801-17, vii. doi: 10.1016/j.mcna.2009.03.007.
4
[Role of surgery in the treatment of refractory ascites in cirrhotic patients].
Ann Chir. 1999;53(10):966-72.
5
[Management of ascitis in patients with cirrhosis].[肝硬化患者腹水的管理]
Tunis Med. 2007 Feb;85(2):91-5.
6
Management of ascites. A review.腹水的管理。综述。
J Med. 1997;28(1-2):21-30.
7
Management of refractory ascites.难治性腹水的处理。
Am J Ther. 2012 Mar;19(2):121-32. doi: 10.1097/MJT.0b013e3181ff7a8b.
8
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis.难治性腹水:肝硬化患者一种严重并发症的发病机制、定义和治疗。
Liver Int. 2010 Aug;30(7):937-47. doi: 10.1111/j.1478-3231.2010.02272.x. Epub 2010 May 21.
9
Management of ascites in patients with chronic liver disease.慢性肝病患者腹水的管理
Am J Gastroenterol. 1994 Nov;89(11):1949-56.
10
Management of ascites in cirrhosis.肝硬化腹水的管理
Clin Liver Dis. 2005 Nov;9(4):715-32, viii. doi: 10.1016/j.cld.2005.07.008.